Literature DB >> 29693485

Toward adaptive deep brain stimulation in Parkinson's disease: a review.

Ameer Mohammed1, Richard Bayford2, Andreas Demosthenous1.   

Abstract

Clinical deep brain stimulation (DBS) is now regarded as the therapeutic intervention of choice at the advanced stages of Parkinson's disease. However, some major challenges of DBS are stimulation induced side effects and limited pacemaker battery life. Side effects and shortening of pacemaker battery life are mainly as a result of continuous stimulation and poor stimulation focus. These drawbacks can be mitigated using adaptive DBS (aDBS) schemes. Side effects resulting from continuous stimulation can be reduced through adaptive control using closed-loop feedback, while those due to poor stimulation focus can be mitigated through spatial adaptation. Other advantages of aDBS include automatic, rather than manual, initial adjustment and programming, and long-term adjustments to maintain stimulation parameters with changes in patient's condition. Both result in improved efficacy. This review focuses on the major areas that are essential in driving technological advances for the various aDBS schemes. Their challenges, prospects and progress so far are analyzed. In addition, important advances and milestones in state-of-the-art aDBS schemes are highlighted - both for closed-loop adaption and spatial adaption. With perspectives and future potentials of DBS provided at the end.

Entities:  

Keywords:  Parkinson's disease; adaptive stimulation; biosignal processing; closed-loop; deep brain stimulation; directional steering; neural control

Mesh:

Year:  2018        PMID: 29693485     DOI: 10.2217/nmt-2017-0050

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  1 in total

1.  Optimization of Surface Electromyography-Based Neurofeedback Rehabilitation Intervention System.

Authors:  Wenlin Sun; Yujun Qi; Yang Sun; Tiantian Zhao; Xiaoyong Su; Yang Liu
Journal:  J Healthc Eng       Date:  2021-03-17       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.